Antithrombotic treatment in atrial fibrillation

Heart

Volumn 93, Issue 1, 2007, Pages 39-44

  Kalra, L ^a   Lip, G Y H ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; PLACEBO; TRIFLUSAL; WARFARIN;

BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CARDIOVERSION; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE CLASSIFICATION; HEART ATRIUM FIBRILLATION; HUMAN; MITRAL VALVE STENOSIS; PATIENT SATISFACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; RISK REDUCTION; SELF MONITORING; SIDE EFFECT; STROKE; SYSTEMATIC REVIEW; THROMBOEMBOLISM; THROMBOGENESIS; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; UNSPECIFIED SIDE EFFECT;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; DRUG MONITORING; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; RISK ASSESSMENT; SELF CARE; THROMBOSIS;

EID: 33846195325     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2006.099911     Document Type: Conference Paper

References (50)

1. Fleming HA, Bailey SM. Mitral valve disease, systemic embolism and anticoagulants. Postgrad Med J 1971;47:599-604.
2. Salem DN, Stein PD, Al-Ahmad A, et al. Antithrombotic therapy in valvular heart disease-native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(Suppl):S457-82.
3. Szekely P. Systemic embolism and anticoagulant prophylaxis in rheumatic heart disease. BMJ 1964;5392:1209-12.
4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991;22:983-8.
5. Petersen P, Madsen EB, Brun B, et al. Silent cerebral infarction in chronic atrial fibrillation. Stroke 1987;18:1098- 100.
6. Wolf PA, Kannel WB, McGee DL, et al. Duration of atrial fibrillation and imminence of stroke: the Framingham study. Stroke 1983;14:664-7.
7. Lip GY, Boos CJ. Antithrombotic treatment in atrial fibrillation. Heart 2006;92:155-61.
8. Sudlow M, Thomson R, Thwaites B, et al. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet 1998;352:1167-71.
9. Brass LM, Krumholz HM, Scinto JM, et al. Warfarin use among patients with atrial fibrillation. Stroke 1997;28:2382-9.
10. Kalra L, Perez I, Melbourn A. Risk assessment and anticoagulation for primary stroke prevention in atrial fibrillation. Stroke 1999;30:1218-22.
11. Perez I, Melbourn A, Kalra L. Use of antithrombotic measures for stroke prevention in atrial fibrillation. Heart 1999;82:570-4.
12. Waldo AL, Becker RC, Tapson VF, et al. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol 2005;46:1729-36.
13. Gottlieb LK, Salem SS. Anticoagulation in atrial fibrillation: does effectiveness in clinical trials translate into effective practice? Arch Intern Med 1994;154:1945-53.
14. Green CJ, Hadorn DC, Bassett K, et al. Anticoagulation in chronic non-valvular atrial fibrillation: a critical appraisal and meta-analysis. Can J Cardiol 1997;13:811-15.
15. Taylor FC, Cohen H, Ebrahim S. Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. BMJ 2001;322:321-6.
16. Lane D, Lip GYH. Anti-thrombotic therapy for atrial fibrillation and patients' preferences for treatment. Age Ageing 2005;34:1-3.
17. Howitt A, Armstrong D. Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation. BMJ 1999;318:1324-7.
18. Kalra L, Yu G, Perez I, et al. A prospective cohort study of anticoagulation for stroke prevention in atrial fibrillation: does trial efficacy translate into clinical effectiveness? BMJ 2000;320:1236- 9.
19. Evans A, Kalra L. Are results of RCT on anticoagulation in AF generalisable to clinical practice. Arch Intern Med 2001;161:1443- 7.
20. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003;290:2685-92.
21. Bradley BC, Perdue KS, Tisdel KA, et al. Frequency of anticoagulation for atrial fibrillation and reasons for its non-use at a Veterans Affairs medical center. Am J Cardiol 2000;85:568-72.
22. Weisbord SD, Whittle J, Brooks RC. Is warfarin really underused in patients with atrial fibrillation? J Gen Intern Med 2001;16:743- 9.
23. Dewilde S, Carey IM, Emmas C, et al. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation, and predictors of such treatment in UK primary care. Heart 2005.
24. Lip GYH, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res 2006;118:321-3.
25. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic treatment in atrial fibrillation: analysis of pooled data from five randomised controlled studies. Arch Intern Med 1994;154:1449-57.
26. Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996;156:409-16.
27. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57.
28. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994;120:897-902.
29. Sam C, Massaro JM, D'Agostino RB Sr, et al. Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framingham Heart Study). Am J Cardiol 2004;94:947-51.
30. Aguilar M, Hart R. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history or stroke or transient ischemic attacks. Cochrane Database Syst Rev 2005;19:CD001925.
31. Stroke Prevention in Atrial Fibrillation Investigators. A differential effect of aspirin in prevention of stroke on atrial fibrillation. J Stroke Cerebrovasc Dis 1993;3:181-8.
32. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
33. DiMarco JP, Flaker G, Waldo AL, et al. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. Am Heart J 2005;149:650-6.
34. Perez-Gomez F, Alegria E, Berjon J, et al. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol 2004;44:1557-66.
35. Hart RG, Pearce LA, Rothbart RM, et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 2000;35:183-7.
36. Gallagher MM, Hennessy BJ, Edvardsson N, et al. Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. J Am Coll Cardiol 2002;40:926-33.
37. Sherman DG, Kim SG, Boop BS, et al. Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) Study. Arch Intern Med 2005;165:1185-91.
38. Flaker GC, Belew K, Beckman K, et al. Asymptomatic atrial fibrillation: demographic features and prognostic information from the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) Study. Am Heart J 2005;149:657-63.
39. Weigner MJ, Caulfield TA, Danias PG, et al. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med 1997;126:615-20.
40. Stoddard MF, Dawkins PR, Prince CR, et al. Transesophageal echocardiographic guidance of cardioversion in patients with atrial fibrillation. Am Heart J 1995;129:1204-15.
41. Rockson SG, Albers GW. Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation. J Am Coll Cardiol 2004;43:929-35.
42. Lip GYH, Lane D, van Walraven C, et al. The additive role of plasma von Willebrand Factor levels to clinical factors for risk stratification in patients with atrial fibrillation. Stroke 2006;37:2294-300.
43. Evans A, Perez I, Yu G, et al. Secondary stroke prevention in atrial fibrillation: lessons from clinical practice. Stroke 2000;32:2106-111.
44. Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke 2005;36:1588-93.
45. Shireman TI, Howard PA, Kresowik TF, et al. Combined anticoagulant antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke 2004;35:2362-7.
46. Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions: the task force for percutaneous coronary interventions of the European Society of Cardiology. Eur Heart J 2005;26:804-47.
47. Lip GYH, Karpha M. Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline. Chest 2006;130:1823-7.
48. Kakar P, Lane D, Lip GYH. Bleeding risk stratification models in deciding on anticoagulation in patients with atrial fibrillation: a useful complement to stroke risk stratification scheme. Chest (in press).
49. Sawicki PT. A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. Working Group for the Study of Patient Self-Management of Oral Anticoagulation. JAMA 1999;281:145-50.
50. Fitzmaurice DA, Machin SJ, British Society of Haematology Task Force for Haemostosis and Thrombosis. Recommendations for patients undertaking self management of oral anticoagulation. BMJ 2001;323:985-9.